Home|Journals|Articles by Year|Audio Abstracts
 

Research Article

ECB. 2018; 7(4): 150-155


ISOLATION, CHEMICAL MODIFICATION AND CYTOTOXIC EVALUATION OF ATRANORIN, THE MAJOR METABOLITE OF THE FOLIOSE LICHEN PARMOTREMA MELANOTHRIX

Uppuluri Venkata Mallavadhani, Tiruveedhula Somasekhar, GudemSagarika, Sistla Ramakrishna.




Abstract

The foliose lichen, Parmotrema melanothrix has been chemically screened for the first time and isolated the depside atranorin (1) in
significant quantity (2 %) along with methyl 2,4-dihydroxy-3,6-dimethylbenzoate (2) and methyl 3-formyl-2,4-dihydroxy-6-
methylbenzoate (3). In view of its abundance, interesting structural features and significant biological profile, atranorin was subjected to
chemical modification and synthesised five diverse analogues in very good yields (70~93%). The synthesised analogues along with the
three isolated compounds were evaluated for their cytotoxic potential against a panel of six human cancer cell lines using MTT assay.
Among the tested compounds, 1a showed enhanced activity than the parent compound (1) against almost all the tested cell lines.
Significantly, 1a showed highest activity (IC50 = 15.19 μM) against prostate cancer cell line (DU145). The results indicate that complete
protection of the phenolic hydroxyls in atranorin as acetates enhances the cytotoxicity, especially against DU 145.

Key words: Lichen, Parmotrema melanothrix, atranorin, cytotoxicity, MTT assay.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.